Quest Diagnostics EVP Doherty sells 22,105 shares
Seven sale tranches were reported under a Rule 10b5-1 sales plan adopted by the executive vice president.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Quest Diagnostics Inc. Executive Vice President Catherine T. Doherty exercised options for 22,105 shares at $121.8050 per share on November 3, 2026; the reported option balance afterward was 0. She received 4,827 restricted stock units and sold 22,105 shares that day under a Rule 10b5-1 sales plan she adopted. The seven weighted-average sale prices were 3,818 at $245.4519, 5,990 at $246.2649, 1,151 at $246.9835, 2,358 at $248.3838, 3,004 at $249.4035, 2,877 at $250.4882, and 2,907 at $251.2386 per share. A separate indirect holding entry reports 4,552 shares through the Company's 401(k) and/or Supplemental Deferred Compensation Plan; the count is based on the company stock-fund account balance, which includes some money market instruments.
Insider Trade Summary 10b5-1
Exercise and Sale: 22,105 shares ($2.79M approx. pre-tax spread)
Exercise and Sale
10 txns
Insider
Doherty Catherine T.
Role
Executive Vice President
Sold
22,105 shs ($5.48M)
Approx. gross sale proceeds
$5.48M
Approx. exercise cost
$2.69M
Approx. pre-tax spread
$2.79M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualifed Stock Option (right to buy) F2, F11 | 22,105 | $121.805 | $2.69M |
| Grant/Award | Common Stock F1 | 4,827 | $0.00 | $0.00 |
| Exercise | Common Stock F2 | 22,105 | $121.805 | $2.69M |
| Sale | Common Stock F2, F3 | 3,818 | $245.4519 | $937K |
| Sale | Common Stock F2, F4 | 5,990 | $246.2649 | $1.48M |
| Sale | Common Stock F2, F5 | 1,151 | $246.9835 | $284K |
| Sale | Common Stock F2, F6 | 2,358 | $248.3838 | $586K |
| Sale | Common Stock F2, F7 | 3,004 | $249.4035 | $749K |
| Sale | Common Stock F2, F8 | 2,877 | $250.4882 | $721K |
| Sale | Common Stock F2, F9 | 2,907 | $251.2386 | $730K |
| Holding | Common Stock F10 | -- | -- | -- |
Holdings After Transaction:
Non-Qualifed Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 71,949 shares (Direct);
Common Stock — 4,552 shares (Indirect, 401(k)/SDCP)
Footnotes (11)
- F1. Represents an award of restricted stock units.
- F2. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
- F3. This transaction was executed in multiple trades at prices ranging from $244.840 to $245.8353. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $245.845 to $246.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $246.850 to $247.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $247.930 to $248.7825. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $249.005 to $250.0008. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $250.005 to $251.0036. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $251.005 to $251.700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F10. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
- F11. The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024.
Key Figures
Options exercised: 22,105 shares
Exercise price: $121.8050 per share
Shares sold: 22,105 shares
+4 more
7 metrics
Options exercised
22,105 shares
November 3, 2026
Exercise price
$121.8050 per share
Options exercised November 3, 2026
Shares sold
22,105 shares
Seven sale tranches on November 3, 2026
Restricted stock unit award
4,827 shares
Awarded November 3, 2026
Options following exercise
0 options
Reported following the November 3, 2026 transaction
Indirect plan shares
4,552 shares
401(k) and/or Supplemental Deferred Compensation Plan; based on the company stock-fund account balance, which includes some money market instruments
Weighted-average sale prices
$245.4519, $246.2649, $246.9835, $248.3838, $249.4035, $250.4882, and $251.2386 per share
Prices for the seven sale tranches on November 3, 2026
Key Terms
Rule 10b5-1 sales plan, restricted stock units, weighted average sale price, Supplemental Deferred Compensation Plan
4 terms
Rule 10b5-1 sales plan financial
"pursuant to a Rule 10b5-1 sales plan adopted by the reporting person"
restricted stock units financial
"Represents an award of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"reflects the weighted average sale price"
Supplemental Deferred Compensation Plan financial
"Supplemental Deferred Compensation Plan"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many DGX options did Catherine T. Doherty exercise, and at what price?
She exercised options covering 22,105 shares at $121.8050 per share on November 3, 2026. The reported option balance following the transaction was 0.
What was Catherine T. Doherty's DGX option vesting schedule?
The options vested in three annual installments: the first on February 17, 2022, the second on February 17, 2023, and the final installment on February 17, 2024.
AI-generated analysis. How Rhea-AI works. Not financial advice.
